Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Permrock Royalty Trust Trust Units

(NYSE: PRT)
Add to Portfolio
-0.16 (-1.97%)
as of Jun 14, 2019

Last 7.97
Change -0.16 (-1.97%)
Open 8.16
Prev. Close 8.13
Today's Range
7.81
8.18
52wk Range
5.45
16.38
Volume 51,600
Avg Volume 54,060
Sector SIC-1311 Crude Petroleum & Natural Gas

Perfomance Comparison

Name Today 3-Month 1-Year
PRT -1.97% -7.86% -50.50%
DJIA -0.07% -0.49% +3.63%
S&P 500 -0.16% +0.47% +3.76%

Key Statistics

Annual EPS N/A
Dividend Yield 13.31%
P/E Ratio N/A
Market Capitalization, $K 98,790
Weighted Alpha -57.80
Standard Deviation -0.85
Profit Margin N/A
Beta N/A

Growth Rates

YTD +34.63%
1-Year -50.50%

Opinion

Sell Hold Buy

Recent Headlines

Littoral Combat Ship 21 (Minneapolis-Saint Paul)

PR Newswire via COMTEX - Sat Jun 15, 04:15PM EDT
The Lockheed Martin (NYSE: LMT)-led shipbuilding team launched Littoral Combat Ship (LCS) 21, the future USS Minneapolis-Saint Paul into the Menominee River at the Fincantieri Marinette Marine Shipyard. Ship sponsor Jodi J. Greene(full story)
LMT: 350.14 (+1.06)

PBF Energy to Attend the J.P. Morgan 2019 Energy

PR Newswire via COMTEX - Sat Jun 15, 02:39PM EDT
PBF Energy Inc. (NYSE: PBF) announced today that the company's management will be attending the J.P. Morgan 2019 Energy Conference being held on June 18-19, 2019.(full story)
PBFX: 19.90 (+0.04), PBF: 23.90 (-0.57)

Sunesis Pharmaceuticals Announces Presentation of

GlobeNewswire via COMTEX - Sat Jun 15, 11:30AM EDT
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company's Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lympho(full story)
SNSS: 0.90 (-0.05)

Editas Medicine Presents Pre-Clinical Data for

GlobeNewswire via COMTEX - Sat Jun 15, 11:30AM EDT
IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia(full story)
EDIT: 21.73 (-0.78)

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP

BusinessWire via COMTEX - Sat Jun 15, 09:30AM EDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Apple, Inc. ("Apple" or the "Company") (NASDAQ:AAPL) of the June 17, 2019 deadline to seek the role of lead plaintiff in a federal (full story)
AAPL: 192.74 (-1.41)